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Background: While long-acting injectable antipsychotics 
(LAIs) are hoped to reduce high relapse rates in schizophre-
nia, recent randomized controlled trials (RCTs) challenged 
the benefits of LAIs over oral antipsychotics (OAPs). 
Methods: Systematic review/meta-analysis of RCTs that 
lasted ≥6  months comparing LAIs and OAPs. Primary 
outcome was study-defined relapse at the longest time 
point; secondary outcomes included relapse at 3, 6, 12, 18, 
and 24 months, all-cause discontinuation, discontinuation 
due to adverse events, drug inefficacy (ie, relapse + discon-
tinuation due to inefficacy), hospitalization, and nonad-
herence. Results: Across 21 RCTs (n = 5176), LAIs were 
similar to OAPs for relapse prevention at the longest time 
point (studies = 21, n = 4950, relative risk [RR] = 0.93, 
95% confidence interval [CI]: 0.80–1.08, P  =  .35). The 
finding was confirmed restricting the analysis to outpa-
tient studies lasting ≥1 year (studies = 12, RR = 0.93, 95% 
CI:0.71–1.07, P = .31). However, studies using first-gener-
ation antipsychotic (FGA)-LAIs (studies = 10, RR = 0.82, 
95% CI:0.69–0.97, P  =  .02) and those published ≤1991 
(consisting exclusively of all 8 fluphenazine-LAI studies; 
RR = 0.79, 95% CI: 0.65–0.96, P = 0.02) were superior to 
OAPs regarding the primary outcome. Pooled LAIs also 
did not separate from OAPs regarding any secondary out-
comes. Again, studies using FGA-LAIs and those published 
≤1991 were associated with LAI superiority over OAPs, eg, 
hospitalization and drug inefficacy. Conclusions: In RCTs, 
which are less representative of real-world patients than nat-
uralistic studies, pooled LAIs did not reduce relapse com-
pared with OAPs in schizophrenia patients. The exceptions 
were FGA-LAIs, mostly consisting of fluphenazine-LAI 
studies, which were all conducted through 1991. Because 
this finding is vulnerable to a cohort bias, studies compar-
ing FGA-LAI vs second-generation antipsychotics-LAI 
and LAI vs OAP RCTs in real-world patients are needed.
Key words: antipsychotics/adherence/depot/long-acting 
injection/meta-analysis/relapse/schizophrenia/treatment 
discontinuation
Introduction
Because psychopathology and social functioning can 
worsen with repeated psychotic episodes in patients with 
schizophrenia,1,2 relapse prevention is critical. There is 
strong evidence of antipsychotic efficacy for relapse preven-
tion in chronic and first-episode patients,3,4 in that the risk of 
relapse is 2–6 times higher without medication.3–6 However, 
because nonadherence rates as high as 50% can limit the 
efficacy of pharmacotherapy,7,8 the use of long-acting 
injectable antipsychotics (LAIs) is an important option.9 In 
practice, patients and clinicians are sometimes reluctant to 
use LAIs because of stigma, needle pain, time constraints, 
side effect concerns, and cost.10 Given these drawbacks to 
the use of LAIs, convincing data showing the superiority of 
LAI over oral antipsychotics (OAPs) is needed to support 
the use of LAIs. The first LAI was introduced in the 1960s. 
Since then, at least 5 first-generation antipsychotics (FGAs)-
LAIs and 3 second-generation antipsychotics (SGA)-LAIs 
have become available. Our previous meta-analysis found 
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that LAIs were associated with significantly lower relapse 
rates than OAPs.11 However, new, large, controlled trials 
showed no benefit of LAIs.12–15 We performed a meta-anal-
ysis that incorporated the new randomized controlled trials 
(RCTs) and also applied broader inclusion criteria. The new 
analyses are based on twice as many studies and 3 times as 
many patients as compared with the earlier ones.
Method
The meta-analysis was performed following PRISMA 
guidelines.16
Search
We conducted a search without language restrictions, 
using MEDLINE/PubMed, Cochrane library, PsycINFO 
and CINAHL (last search: 06/2012), for RCTs of relapse 
prevention or maintenance treatment in schizophrenia 
and related disorders lasting ≥6  months. To avoid publi-
cation bias, we also included unpublished studies, such as 
conference proceedings and clinical trial registries (http://
clinicaltrials.gov/). Search terms included synonyms of (1) 
antipsychotic(s); (2) schizophrenia and related disorders, 
(3) randomized; and (4) depot, (long-acting) injection(s), 
microsphere, decanoate, palmitate, enanthate. The elec-
tronic search was supplemented by hand search of refer-
ence lists of relevant publications. At least 2 independent 
investigators (TK, AR, CL) conducted the literature search.
Inclusion Criteria
We included randomized, head-to-head comparisons 
of LAI vs OAP for relapse prevention or maintenance 
treatment in schizophrenia. Patients in studies had to be 
≥17  years old and have diagnoses of schizophrenia or 
schizoaffective disorder according to study diagnoses, 
but we included studies having other diagnoses, such as 
schizophreniform disorder, if  schizophrenia or schizo-
affective disorder were the vast majority of the study 
population. We included studies with a duration of at 
least 24 weeks and that provided information about 
relapse-related information, such as study-defined relapse 
or rehospitalization. We excluded penfluridol, a once-
weekly OAP, considering it neither a LAI nor OAP.
Data Extraction and Outcomes
Data were extracted independently by ≥2 reviewers (TK, 
AR, CL, SL, CC). Authors and companies were con-
tacted to provide missing information and unpublished 
data. Any disagreements were resolved by discussion.
The primary outcome was study-defined relapse at the 
latest point of follow-up. Where possible, the relapse rate 
was based on survival curves (which estimate relapse and 
take account of dropouts), but in other cases, relapse was 
based on the initial number of patients at risk. In those 
cases where the paper did not define relapse, we used the 
next most-appropriate outcome, typically hospitalization 
or psychotic exacerbation (table 1).
Secondary outcomes included relapse at 3, 6, 12, 18, 
and 24 months, all-cause discontinuation, discontinuation 
due to adverse events, drug inefficacy (defined as relapse 
+ discontinuation due to inefficacy; or defined as relapse 
when the overlap with discontinuation due to inefficacy 
was unclear), hospitalization, and nonadherence (defined 
as discontinuation due to nonadherence or study-defined 
nonadherence; see online supplementary figure 10).
Data Analysis
We used 2 population sets: (1) the “randomized” or 
“intent-to-treat” (IIT) population, where patients who 
dropped out due to group assignment are included in the 
analysis and (2) the “safety and/or efficacy” population, 
which includes only those patients who took ≥1 dose and 
received at least one postbaseline assessment. In contrast 
to our previous report where the randomized sample was 
primary, in this analysis the safety/efficacy population was 
primary, while the randomized population was examined 
in secondary analyses. All outcomes were dichotomous. 
The comparison of LAI vs OAP was performed (1) for 
each LAI individually (fluphenazine, risperidone, etc) and 
(2) across all pooled LAIs. In each analysis, we computed 
the pooled RR with its 95% confidence interval (CI) using 
the random-effects model.17 Number-needed-to-treat 
(NNT) was calculated where appropriate. With regard to 
the heterogeneity, τ², I2, Q, and P-values are reported.
In addition to the primary and secondary outcome anal-
yses, we conducted a series of subgroup/sensitivity analyses. 
In order to assess the robustness of the primary outcome, we 
repeated the analyses using relapse rates based on the initial 
sample size (where available, as well as exclusively), whereas 
the primary analysis employed relapse rates based on sur-
vival curves (where available, as well as exclusively). While 
the primary analysis was based on the full set of studies, we 
also conducted analyses on subgroups (identified a priori) 
of studies in order to identify potential methodological 
biases or different populations. These included subgroups 
based on (1) medication group (FGA-LAI vs SGA-LAI), 
(2) publication year (older RCTs [published ≤1991] vs newer 
RCTs [published ≥2005]); there was a 14 year gap between 
the last study published in 1991 and the next study published 
in 2005, (3) treatment concealment (double-blind double-
dummy vs rater-masked vs open label), (4) in-/outpatient 
status (outpatients at baseline or shortly after initiation of 
antipsychotic treatment vs mixed patient status [in-/outpa-
tients mixed or inpatients throughout the study]), (5) study 
duration (≥1 year vs <1 year), and (6) medication allocation 
(same vs different antipsychotics in LAI and OAP arm). 
Finally, we also reexamined the results with the same inclu-
sion criteria applied in the previous, more restricted meta-
analysis,11 ie, outpatient studies lasting ≥1 year.
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Long-Acting Injectable vs Oral Antipsychotics
In post-hoc analyses, we compared the chlorpromazine 
(CPZ) equivalents between the LAI arm and OAP arm 
in the following study groups in order to identify poten-
tial confounders: all studies, using the same or different 
antipsychotic in the LAI and OAP groups, FGA- or 
SGA-LAI studies, and older or newer studies. We also 
compared mean CPZ equivalents within each of the OAP 
and LAI arms between FGA- vs SGA-LAI studies and 
between older vs newer studies. Antipsychotic doses were 
converted to CPZ equivalents using published guide-
lines.18–20 For LAIs, we used the manufacturers’ recom-
mended equivalent for the depot to oral conversion for the 
same drug and then converted to oral CPZ equivalents.
Data were entered into a funnel graph (trial effect 
against trial size) to investigate the likelihood of overt 
publication bias.21 Data were double entered into Review 
Manager 5.1.4 (Cochrane Collaboration, http://ims.
cochrane.org/revman).
Results
Search and Study Characteristic
We identified 21 RCTs with 5176 participants (see online 
supplementary figure  1). One study22 was excluded 
because it did not quantify the number of patients at risk 
but reported only completed cases.
The number of patients per study ranged from 31–921 
(median: 105), and mean study duration was 66.4 ± 32.2 
(range: 24–130) weeks; duration: <1year: studies  =  4, 
≥1year: studies  =  17). Nine studies had a double-blind, 
double-dummy design, 5 were rater-masked, and 7 were 
open. There were 10 FGA-LAI and 11 SGA-LAI stud-
ies. The number of studies with each individual LAI were 
fluphenazine = 8, haloperidol = 1, zuclopenthixol = 1, ris-
peridone = 9, olanzapine = 2. The number of the studies 
with each OAP were fluphenazine = 4, pimozide = 2, halo-
peridol = 1, trifluoperazine = 1, zuclopenthixol = 1, olanza-
pine = 4, quetiaapine = 2, risperidone = 2, aripiprazole = 2, 
and previous medication/physicians’ choice  =  3. Eleven 
studies (52.4%) used different antipsychotics in the 2 arms. 
Thirteen studies (61.9%) included only outpatients, 2 (9.5%) 
included inpatients at baseline who were discharged shortly 
after study initiation,12,15 1 (4.8%) required patients to be 
hospitalized throughout the trial,23 while 5 (23.8%) provided 
insufficient information. Relapse definitions varied. In 9 
studies (42.9%), relapse was not defined. In 3 of these, we 
used hospitalization rate as relapse12,24,25; in the remaining 6, 
we utilized study-defined symptomatic worsening (table 1).
Relapse Rate at the Longest Study Time Point
Analyzing individual LAIs, fluphenazine-LAI showed 
significant superiority over OAPs (studies  =  8, n  =  826, 
RR  =  0.79, 95% CI: 0.65–0.96, P  =  .02, I2  =  23%, 
NNT  =  13), while the other LAIs were not significantly 
superior to OAPs (pooled RRs for each LAI ranged 
from 0.99–1.28). When pooled together, the risk for LAIs 
was similar to the risk for OAPs (studies = 21, n = 4950, 
RR = 0.93, 95% CI: 0.80–1.08, P = .35). The risk ratio var-
ied across studies (τ2 = 0.05, I2 = 58%, Q = 47.31, df = 20, 
P = .0005) (figure 1).
Relapse Rate at Specific Time Points
Comparing relapse rates at different time points (3, 6, 12, 
18, and 24 months), pooled LAIs did not separate from 
OAPs (see online supplementary figures  2, 3, 4, 5, 6). 
A single study of fluphenazine depot yielded trend-level 
superiority at 18 months (study = 1, n = 105, RR = 0.66, 
95% CI: 0.44–0.99, P =  .05) and significant superiority 
at 24 months (study = 1, n = 105, RR = 0.56, 95% CI: 
0.38–0.80, P = .002); 2 studies of olanzapine-LAI yielded 
trend-level inferiority at 6 months (studies = 2, n = 1445, 
RR = 1.27, 95% CI: 0.97–1.66, P = .09).
All-Cause Discontinuation
Neither individual LAI nor pooled LAIs separated from 
OAPs regarding all-cause discontinuation (pooled LAIs: 
studies = 21, n = 4882, RR = 1.00, 95% CI: 0.89–1.13, 
P = .99) (figure 2).
Discontinuation Due to Adverse Events
Neither individual nor pooled LAIs separated from 
OAPs regarding discontinuation due to adverse events in 
the safety/efficacy (pooled LAIs: studies = 19, n = 4662, 
RR = 1.10, 95% CI: 0.74–1.64, P = .65) (see online sup-
plementary figure 7).
Drug Inefficacy
Among individual LAIs, only fluphenazine was superior 
to OAPs regarding drug inefficacy defined as relapse + 
discontinuation due to inefficacy (studies = 8, n = 826, 
RR = 0.78, 95% CI: 0.66–0.91, P = .002) in the safety/effi-
cacy population. Conversely, olanzapine-LAI was infe-
rior to OAP on this measure (n = 1445, RR = 1.52, 95% 
CI: 1.12–2.07, P  =  .007), but this was based on only 2 
studies. Pooled LAIs did not separate from OAPs regard-
ing drug inefficacy (see online supplementary figure 8).
Hospitalization
Among individual LAIs, only fluphenazine-LAI was 
superior to OAPs in preventing hospitalization (stud-
ies = 4, n = 197, RR = 0.82, 95% CI: 0.67–0.99, P = .04). 
Pooled LAIs showed trend-level superiority over OAPs 
(studies = 10, RR = 0.89, 95% CI: 0.78–1.02, P = .09) (see 
online supplementary figure 9).
Nonadherence
Only 2 studies utilized pill counts or urine concentra-
tion.26,27 One zuclopenthixol study yielded trend-level 
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Study or Subgroup
1.7.1 Relapse (estimated rate preferred, longest time point) - Fluphenazine depot
Barnes 1983
Crawford 1974
Del Guidice 1975
Falloon 1978
Hogarty 1979
Kaneno 1991
Rifkin 1977
Schooler 1980
Subtotal (95% CI)
Total events
Heterogeneity: Tau² = 0.02; Chi² = 9.06, df = 7 (P = 0.25); I² = 23%
Test for overall effect: Z = 2.33 (P = 0.02)
1.7.2 Relapse (estimated rate preferred, longest time point) - Haloperidol depot
Glick 2005
Subtotal (95% CI)
Total events
Heterogeneity: Not applicable
Test for overall effect: Z = 0.03 (P = 0.97)
1.7.3 Relapse (estimated rate preferred, longest time point) - Olanzapine LAI
Detke 2011
Kane 2010
Subtotal (95% CI)
Total events
Heterogeneity: Tau² = 0.03; Chi² = 1.77, df = 1 (P = 0.18); I² = 44%
Test for overall effect: Z = 0.45 (P = 0.65)
1.7.4 Relapse (estimated rate preferred, longest time point) - Risperidone LAI
Bai 2007
Gaebel 2010
Kamijima 2009
Keks 2007
MacFadden 2010
NCT00246259
Potapov 2008
Rosenheck 2011
Schooler 2011
Subtotal (95% CI)
Total events
Heterogeneity: Tau² = 0.09; Chi² = 30.92, df = 8 (P = 0.0001); I² = 74%
Test for overall effect: Z = 0.15 (P = 0.88)
1.7.5 Relapse (estimated rate preferred, longest time point) - Zuclopenthixol depot
Arango 2006
Subtotal (95% CI)
Total events
Heterogeneity: Not applicable
Test for overall effect: Z = 0.59 (P = 0.56)
Total (95% CI)
Total events
Heterogeneity: Tau² = 0.05; Chi² = 47.31, df = 20 (P = 0.0005); I² = 58%
Test for overall effect: Z = 0.93 (P = 0.35)
Test for subgroup differences: Chi² = 3.99, df = 4 (P = 0.41), I² = 0%
Events
3
2
21
8
22
8
2
54
120
5
5
102
58
160
2
65
18
25
90
11
4
86
75
376
10
10
671
Total
19
14
27
20
55
127
23
107
392
9
9
264
599
863
23
327
147
247
177
32
20
187
146
1306
26
26
2596
Events
3
6
59
5
36
9
3
61
182
9
9
104
23
127
0
136
5
27
82
5
8
90
62
415
6
6
739
Total
17
15
61
24
50
132
28
107
434
16
16
260
322
582
25
371
51
300
172
31
20
182
150
1302
20
20
2354
Weight
0.9%
1.0%
9.6%
2.0%
6.8%
2.1%
0.7%
8.8%
32.0%
3.1%
3.1%
9.5%
5.5%
14.9%
0.2%
8.7%
2.1%
4.8%
9.4%
2.1%
1.8%
9.4%
8.9%
47.4%
2.5%
2.5%
100.0%
M-H, Random, 95% CI
0.89 [0.21, 3.85]
0.36 [0.09, 1.48]
0.80 [0.65, 0.99]
1.92 [0.74, 4.95]
0.56 [0.38, 0.80]
0.92 [0.37, 2.32]
0.81 [0.15, 4.45]
0.89 [0.69, 1.14]
0.79 [0.65, 0.96]
0.99 [0.48, 2.04]
0.99 [0.48, 2.04]
0.97 [0.78, 1.19]
1.36 [0.85, 2.16]
1.08 [0.78, 1.47]
5.42 [0.27, 107.20]
0.54 [0.42, 0.70]
1.25 [0.49, 3.19]
1.12 [0.67, 1.89]
1.07 [0.86, 1.32]
2.13 [0.84, 5.43]
0.50 [0.18, 1.40]
0.93 [0.75, 1.15]
1.24 [0.97, 1.59]
0.98 [0.75, 1.28]
1.28 [0.56, 2.93]
1.28 [0.56, 2.93]
0.93 [0.80, 1.08]
LAI OAP Risk Ratio Risk Ratio
M-H, Random, 95% CI
0.05 0.2 1 5 20
Favours LAI Favours OAP
Fig. 1. Relapse rate-estimated rate preferred, longest time point (safety/efficacy population).
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1.1.1 All-cause discontinuation - Fluphenazine depot
Barnes 1983
Crawford 1974
Del Guidice 1975
Falloon 1978
Kaneno 1991
Rifkin 1977
Schooler 1980
Subtotal (95% CI)
Total events
Heterogeneity: Tau² = 0.04; Chi² = 8.18, df = 6 (P = 0.22); I² = 27%
Test for overall effect: Z = 0.03 (P = 0.98)
1.1.2 All-cause discontinuation - Haloperidol depot
Glick 2005
Subtotal (95% CI)
Total events
Heterogeneity: Not applicable
Test for overall effect: Z = 0.65 (P = 0.52)
1.1.3 All-cause discontinuation - Olanzapine LAI
Detke 2011
Kane 2010
Subtotal (95% CI)
Total events
Heterogeneity: Tau² = 0.06; Chi² = 6.28, df = 1 (P = 0.01); I² = 84%
Test for overall effect: Z = 1.15 (P = 0.25)
1.1.4 All-cause discontinuation - Risperidone LAI
Bai 2007
Gaebel 2010
Kamijima 2009
Keks 2007
MacFadden 2010
NCT00246259
Potapov 2008
Rosenheck 2011
Schooler 2011
Subtotal (95% CI)
Total events
Heterogeneity: Tau² = 0.04; Chi² = 21.07, df = 8 (P = 0.007); I² = 62%
Test for overall effect: Z = 0.02 (P = 0.98)
1.1.5 All-cause discontinuation - Zuclopenthixol depot
Arango 2006
Subtotal (95% CI)
Total events
Heterogeneity: Not applicable
Test for overall effect: Z = 0.77 (P = 0.44)
Total (95% CI)
Total events
Heterogeneity: Tau² = 0.04; Chi² = 44.31, df = 19 (P = 0.0009); I² = 57%
Test for overall effect: Z = 0.45 (P = 0.65)
Test for subgroup differences: Chi² = 2.29, df = 4 (P = 0.68), I² = 0%
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13
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107
5
5
145
180
325
3
178
37
87
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8
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2
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Total
19
14
27
20
127
23
107
337
10
10
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146
1320
26
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5
6
17
8
16
7
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125
12
12
136
64
200
0
253
12
114
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568
3
3
908
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19
19
260
322
582
25
382
51
300
176
35
20
182
150
1321
20
20
2326
Weight
1.4%
0.8%
2.7%
2.3%
2.8%
2.6%
9.2%
21.9%
2.7%
2.7%
10.7%
8.7%
19.4%
0.2%
11.4%
3.8%
9.3%
7.2%
4.7%
2.6%
7.8%
8.4%
55.5%
0.6%
0.6%
100.0%
M-H, Random, 95% CI
0.89 [0.31, 2.56]
0.36 [0.09, 1.48]
1.06 [0.52, 2.16]
1.20 [0.55, 2.62]
0.84 [0.42, 1.68]
2.26 [1.08, 4.71]
0.88 [0.70, 1.11]
1.00 [0.75, 1.34]
0.79 [0.39, 1.61]
0.79 [0.39, 1.61]
1.05 [0.90, 1.23]
1.51 [1.18, 1.94]
1.24 [0.86, 1.81]
7.58 [0.41, 139.32]
0.82 [0.72, 0.92]
1.07 [0.61, 1.89]
0.93 [0.74, 1.16]
1.04 [0.75, 1.44]
0.67 [0.41, 1.08]
0.89 [0.43, 1.83]
1.20 [0.90, 1.61]
1.38 [1.06, 1.80]
1.00 [0.83, 1.19]
0.51 [0.09, 2.78]
0.51 [0.09, 2.78]
1.03 [0.90, 1.18]
LAI OAP Risk Ratio Risk Ratio
M-H, Random, 95% CI
0.05 0.2 1 5 20
Favours LAI Favours OAP
Fig. 2. All-cause discontinuation (safety/efficacy population).
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superiority regarding adherence (study  =  1, n  =  46, 
RR  =  0.26, 95% CI: 0.06–1.14, P  =  .07). Pooled LAIs 
did not separate from OAPs (studies  =  10, n  =  2018, 
RR = 0.77, 95% CI: 0.49–1.22, P = .22; see online supple-
mentary figure 10).
Sensitivity and Subgroup Analyses: Primary Outcome
Pooled LAIs did not separate from OAPs whether raw 
relapse rates were used preferentially over estimated 
relapse rates (P =  .49), or whether only estimated rates 
(P = .25) or raw rates (P = .48) were used.
Nonsuperiority of LAIs over OAP remained in all clin-
ically relevant subpopulations and treatment groups, ie, 
treatment concealment (double-blind, double-dummy vs 
rater-masked vs open label), in-/outpatient status, study 
duration (≥1 year, or <1 year), using the same vs different 
medication in the LAI and OAP arm (table 2). When we 
repeated the analyses with more stringent inclusion crite-
ria, which we had applied in our previous meta-analysis,11 
ie, outpatient study lasting ≥1  year, pooled LAIs again 
did not separate from OAPs (studies  =  12, n  =  2162, 
RR = 0.93, 95% CI:0.71–1.07; table 2).
Analyzing FGA-LAIs and SGA-LAIs separately, 
FGA-LAIs were significantly superior to OAPs in pre-
venting relapse (studies  =  10, n  =  897, RR  =  0.82, 
95% CI: 0.69–0.97, P  =  .02, NNT  =  15). However, 
SGA-LAIs did not separate from OAPs (studies  =  11, 
n  =  4053, RR  =  1.00, 95% CI: 0.81–1.23, P  =  1.0; fig-
ure 3). Nevertheless, effect sizes for FGA-LAIs and SGA-
LAIs were not significantly different from each other 
(P = 0.14). Furthermore, the superiority of FGA-LAIs, 
was moderated by publication year. In RCTs published 
until 1991 (studies = 8, n = 826, RR = 0.79, 95% CI: 0.65–
0.96, P = .02, I2 = 23, NNT = 13), consisting exclusively 
of all fluphenazine LAIs, LAIs were superior to OAPs. 
However, this was not the case in the newer RCTs pub-
lished since 2005 (studies = 13, n = 4124, RR = 1.01, 95% 
CI: 0.83–1.22, P = .94), which included only 2/10 FGA-
LAI studies; figure 3).
Subgroup Analyses: Secondary Outcome
Limiting the sensitivity analyses to variables that showed 
a significant effect on the treatment comparison, supe-
riority of FGA-LAIs over OAPs but not of SGA-LAIs 
over OAPs was also apparent regarding some second-
ary outcomes, such as drug inefficacy or hospitalization. 
However, again, the results were moderated by publica-
tion year (table 2).
CPZ Dose Within and Across Studies
Only 13 of the 21 studies (61.9%) reported mean dose 
levels in both treatment arms. Converting antipsychotic 
doses to CPZ equivalents, we found no significant dif-
ferences between LAI and OAP CPZ equivalents across 
all studies (studies  =  13, P  =  .11), within studies using 
the same antipsychotics in the LAI and OAP arms (stud-
ies = 8, P = .95), FGA-LAI studies (studies = 5, P = .63), 
SGA-LAI studies (studies = 8, P = .15), and older stud-
ies (studies  =  3, P  =  1.0). However, there was a trend-
level difference for higher CPZ equivalents in OAP arms 
compared with LAI arms within studies using different 
antipsychotics (studies = 5, P = .06) and in newer studies 
(studies = 10, P = .06).
Comparing FGA- and SGA-LAI studies, there was a 
trend-level difference for higher CPZ equivalent doses in 
FGA-LAI studies in both LAI arms (15 treatment arms, 
P  =  .08) and OAP arms (14 treatment arms, P  =  .08). 
Moreover comparing older vs newer studies, CPZ equiva-
lent doses were significantly higher both in the LAI arms 
(15 treatment arms, P =  .01) and in the OAP arms (14 
treatment arms, P = .03) of the older studies.
Randomized Population
Using the randomized population, the results did not 
change, except for few minor variations: fluphenazine-
LAI showed trend level superiority over OAP regarding 
relapse at 3 months (P = .06) and at 12 months (P = .08), 
hospitalization for pooled LAIs did not reach statistical 
significance (P = 0.14), and double-blind double-dummy 
study design was associated with trend-level superiority 
of LAIs vs OAPs (P = .09).
Publication Bias
The symmetrical funnel-plot did not suggest overt publi-
cation bias (see online supplementary figure 11).
Discussion
To our knowledge, this is the largest meta-analysis com-
paring LAI vs OAP efficacy for relapse prevention in 
schizophrenia. Compared with our prior meta-analy-
sis,11 we broadened the inclusion criteria by incorporat-
ing studies that enrolled inpatients and outpatients, and 
also by including studies lasting 6  months to <1  year. 
However, at the same time, we also examined the result 
within the studies meeting our previous inclusion criteria 
(outpatient study, lasting ≥1 year).
We found that pooled LAIs were not superior to OAPs 
in all of  the examined relapse-related outcomes. The 
only exception was fluphenazine-LAI, which showed 
significant superiority over OAPs in several relapse-
related outcomes. This lack of  superiority of  LAIs is in 
contrast to our previous meta-analysis,11 which showed 
significant superiority of  LAIs over OAPs in schizo-
phrenia with a NNT  =  10. However, this difference 
is not due to the use of  broadened inclusion criteria 
for analyzed studies, as results were similar when the 
analyses were limited to the outpatient studies lasting 
≥1  year. Rather, the nonsuperiority of  LAIs vs OAPs 
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in the extended analyses of  our study was due to a shift 
in the RR toward the null hypothesis rather than due 
to increased imprecision indicated by a widening of  the 
CI. In fact, the CI of  our primary result was slightly 
narrower than in the prior meta-analysis (RR  =  0.93 
[95% CI: 0.80–1.08] vs RR= 0 .70 (95% CI: 0.57–0.87]), 
suggesting that the point estimate was, if  anything, 
somewhat more precise.
On the other hand, we found in subgroup analyses 
that FGA-LAIs studies or older RCTs showed significant 
superiority of LAIs over OAPs but that this was not the 
case in SGA-LAIs studies or newer RCTs. (In a byline, 
Study or Subgroup
2.12.1 FGA-LAIs </=1991
Barnes 1983
Crawford 1974
Del Guidice 1975
Falloon 1978
Hogarty 1979
Kaneno 1991
Rifkin 1977
Schooler 1980
Subtotal (95% CI)
Total events
Heterogeneity: Tau² = 0.02; Chi² = 9.06, df = 7 (P = 0.25); I² = 23%
Test for overall effect: Z = 2.33 (P = 0.02)
2.12.2 FGA-LAIs >/=2005
Arango 2006
Glick 2005
Subtotal (95% CI)
Total events
Heterogeneity: Tau² = 0.00; Chi² = 0.23, df = 1 (P = 0.63); I² = 0%
Test for overall effect: Z = 0.36 (P = 0.72)
2.12.3 SGA-LAIs >/=2005
Bai 2007
Detke 2011
Gaebel 2010
Kamijima 2009
Kane 2010
Keks 2007
MacFadden 2010
NCT00246259
Potapov 2008
Rosenheck 2011
Schooler 2011
Subtotal (95% CI)
Total events
Heterogeneity: Tau² = 0.07; Chi² = 32.93, df = 10 (P = 0.0003); I² = 70%
Test for overall effect: Z = 0.01 (P = 0.99)
Total (95% CI)
Total events
Heterogeneity: Tau² = 0.05; Chi² = 47.31, df = 20 (P = 0.0005); I² = 58%
Test for overall effect: Z = 0.93 (P = 0.35)
Test for subgroup differences: Chi² = 3.18, df = 2 (P = 0.20), I² = 37.1%
Events
3
2
21
8
22
8
2
54
120
10
5
15
2
102
65
18
58
25
90
11
4
86
75
536
671
Total
19
14
27
20
55
127
23
107
392
26
9
35
23
264
327
147
599
247
177
32
20
187
146
2169
2596
Events
3
6
59
5
36
9
3
61
182
6
9
15
0
104
136
5
23
27
82
5
8
90
62
542
739
Total
17
15
61
24
50
132
28
107
434
20
16
36
25
260
371
51
322
300
172
31
20
182
150
1884
2354
Weight
0.9%
1.0%
9.6%
2.0%
6.8%
2.1%
0.7%
8.8%
32.0%
2.5%
3.1%
5.6%
0.2%
9.5%
8.7%
2.1%
5.5%
4.8%
9.4%
2.1%
1.8%
9.4%
8.9%
62.4%
100.0%
M-H, Random, 95% CI
0.89 [0.21, 3.85]
0.36 [0.09, 1.48]
0.80 [0.65, 0.99]
1.92 [0.74, 4.95]
0.56 [0.38, 0.80]
0.92 [0.37, 2.32]
0.81 [0.15, 4.45]
0.89 [0.69, 1.14]
0.79 [0.65, 0.96]
1.28 [0.56, 2.93]
0.99 [0.48, 2.04]
1.11 [0.64, 1.91]
5.42 [0.27, 107.20]
0.97 [0.78, 1.19]
0.54 [0.42, 0.70]
1.25 [0.49, 3.19]
1.36 [0.85, 2.16]
1.12 [0.67, 1.89]
1.07 [0.86, 1.32]
2.13 [0.84, 5.43]
0.50 [0.18, 1.40]
0.93 [0.75, 1.15]
1.24 [0.97, 1.59]
1.00 [0.81, 1.23]
0.93 [0.80, 1.08]
LAI OAP Risk Ratio Risk Ratio
M-H, Random, 95% CI
0.05 0.2 1 5 20
Favours LAI Favours OAP
Fig. 3. Subgroup analysis comparing (1) FGA-LAI studies published ≤1991, (2) FGA-LAI studies published ≥2005, (3) SGA-LAI 
studies published ≥2005.
When FGA-LAIs (combining the top two groups) and second-generation antipsychotics (SGA)-LAIs (bottom group) were analyzed 
separately, FGA-LAIs were significantly superior to OAPs in preventing relapse (Studies = 10, n = 897, RR = 0.82, 95% CI: 0.69–0.97, 
P = 0.02, NNT = 15, heterogeneity: τ2 = 0.01, I2 = 15%, Q = 10.62, df = 9, P = 0.30), but SGA-LAIs were not (Studies = 11, n = 4053, 
RR = 1.00, 95% CI: 0.81–1.23, P = 0.99, heterogeneity: τ2 = 0.07, I2 = 70%, Q = 32.93, df = 10, P = 0.0003). When older randomized 
controlled trials (RCTs) (<1991) (top group) and the remaining newer RCTs (>2005) (combining the bottom two groups) were analyzed 
separately, LAIs had lower relapse rates in older RCTs (Studies = 8, n = 826, RR = 0.79, 95% CI: 0.65–0.96, P = 0.02, NNT = 13, 
heterogeneity: τ2 = 0.02, I2 = 23%, Q = 9.06, df = 7, P = 0.25), but not in the remaining newer RCTs (Studies = 13, n = 4950, RR = 1.01, 
95% CI: 0.83–1.08, P = 0.95, heterogeneity: τ2 = 0.06, I2 = 64%, Q = 33.39, df = 12, P = 0.0008).
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we note that the distinction between FGAs and SGAs 
is a questionable one.)28 However these findings require 
cautionary interpretation. Eight out of 10 FGA-LAI 
studies were published by 1991, and all 8 RCTs published 
by 1991 employed exclusively fluphenazine-LAI. Hence, 
these distinctions were nearly equal, and it is impos-
sible to disentangle the potential reasons for different 
effect sizes. Moreover, the subgroup analysis comparing 
the effect sizes of FGA-LAIs and SGA-LAIs relative to 
OAPs did not yield a significant difference, suggesting 
that in this indirect comparison, there was no indication 
that FGA-LAIs are superior to SGA-LAIs. That being 
said, we consider the following explanations for the dif-
ferential findings for FGA-LAIs (or older RCTs). One 
possibility is publication bias. Because the registration 
system of clinical trials has been introduced, companies 
are obliged to either publish all studies or make the data 
publically available, while in earlier years, studies showing 
less advantages for LAIs may not have been published. 
Another possibility is changing definitions of relapse. 
In order to mitigate potential adverse consequences of 
participating in clinical trials, recent studies tended to 
utilize lower thresholds for relapse, which can increase 
the rate of false positives. From the definitions encoun-
tered in these analyses, this tendency was not obvious 
(see table 1). However, it is hard to rule out this possibil-
ity, as some older studies used vague definitions rather 
than quantitative measures, such as predefined changes in 
PANSS score. In addition to various definitions, thresh-
olds used to determine relapse can also have a big impact. 
For example, hospitalization as threshold is susceptible to 
health insurance system variations, social supports, or cli-
nician’s judgment and can differ by geographical regions 
or over time. Furthermore, the OAPs used in FGA-LAI 
studies published until 1991 were FGAs, while OAPs 
used in SGA-LAI studies published since 2005 were 
generally SGAs. One can argue that patients allocated 
to FGA-OAPs might have a greater chance of relapse, 
either due to poorer adherence or differences in neuro-
pharmacologic properties compared with SGA-OAPs. 
This could be consistent with our recent meta-analysis 
comparing oral SGAs and FGAs, which showed a small 
but significant superiority of SGAs in preventing relapse, 
but due to limited information, we could not determine 
whether nonadherence was a factor.29 We examined this 
possibility in the current analyses as well, but we did not 
find significant group differences. However, adherence 
is rarely assessed directly, and the evaluations involving 
these outcomes are very crude, which is a major limita-
tion of the available RCTs. LAIs are thought to be better 
via improved adherence, not via intrinsically better effi-
cacy. Therefore, it is unclear whether LAIs were not supe-
rior because compliance with OAPs was good enough in 
the context of RCTs.
Regarding CPZ equivalent doses, there were some 
significant or trend-level differences within and across 
studies. CPZ equivalents trended toward being higher in 
OAP arms compared with LAI arms within studies using 
different antipsychotics, which may have disadvantaged 
the LAI arms. However, in the studies that used the same 
medications in the LAI and OAP arm and used also simi-
lar CPZ equivalent doses in both arms, there was also 
no difference in terms of preventing relapse. In SGA-
LAI studies, or newer studies, CPZ equivalent doses in 
the OAP arms also trended to be higher than in the LAI 
arms. In addition, CPZ equivalent dosages used in FGA-
LAI studies and in older studies were at a trend level 
and significantly higher than in SGA-LAI studies and in 
newer studies, respectively. These findings are consistent 
with a trend toward using lower antipsychotic doses since 
the more widespread use of SGAs. Whether or not this 
difference is relevant for the superiority of FGA–LAIs 
and older studies that used higher doses in both the 
LAI and OAP arms than SGA-LAI and newer studies 
that used lower doses in both arms is unclear. However, 
it is possible that higher LAI doses were more effective 
in showing superiority over OAPs, which may have been 
dosed higher than necessary leading to dropout or non-
adherence due to extrapyramidal side effects. However, 
the interpretability of the results of potential dose dif-
ferences is limited by missing information on mean doses 
in the LAI and OAP arms, especially in old studies, and 
by substantial differences in the suggested conversion fac-
tors from antipsychotic doses to CPZ equivalents, both of 
which applied mostly to older studies using FGA-LAIs.
In contrast to our results, recent naturalistic studies 
support the advantages of LAIs over OAPs in relapse 
prevention30–32 as do mirror image studies.33,34 Tiihonen 
et al.31 reported in a nationwide cohort that the risk of 
rehospitalization with LAIs was one-third that of OAPs. 
Most LAIs showed significant superiority compared 
with each OAP counterpart regarding all-cause discon-
tinuation. These results are especially important given 
the potentially conservative bias in that the patients who 
receive doctor’s choice LAIs are more likely to be non-
adherent and more severely ill compared with patients 
receiving doctor’s choice OAPs. Moreover, patients con-
senting to clinical trials of LAIs may not be represen-
tative of those prescribed LAIs in real-world settings.35 
Participants in clinical trials might overrepresent patients 
with better engagement with health care providers, bet-
ter adherence to the treatment, lower illness severity, 
and better cognitive capabilities to understand complex 
issues. This difference in procedures can potentially lead 
to a cohort bias in that less severely ill patients could be 
enrolled in newer trials, particularly with increasing strin-
gency of consent processes. This may explain the differ-
ent results of older vs newer studies.
It is also important to recognize that participation in 
a controlled trial alters the ecology of treatment deliv-
ery and experience. Patients in clinical trials are likely to 
receive more and different types of attention than those 
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in routine care, from measures of adherence to reminders 
to attend clinical/research assessment sessions, or to the 
provision of free medication.36 In addition, more frequent 
monitoring during a trial enables psychiatrists to change 
dosages according to the symptoms and provide support-
ive psychotherapy. It is difficult to determine what role 
these factors might have in altering patterns of medica-
tion-taking in contrast to routine care and to what extent 
they might, therefore, diminish the potential advantages 
of LAIs in RCTs. The substantial disparity between the 
large naturalistic cohort study results and those of RCTs 
in this context would support such concerns.
To this point, we have assumed that LAIs must be more 
effective than OAPs and have been trying to understand 
why this is not apparent in the RCTs. We should also con-
sider the possibility that if  patients are fully adherent with 
OAPs, the OAPs may actually be more efficacious than 
LAIs as suggested by 2 recent trials.23,37,38 One interesting 
hypothesis is the potential supersensitivity of the dopa-
mine D2 receptor. Long-term, continuous D2 blockade 
may increase the number and/or high-affinity state of 
dopamine receptors.39,40 In addition, there are data sug-
gesting that transient, rather than continuous blockade 
of D2 receptors by “extended dosing” (eg, every other 
day dosing), may be more efficacious in both animal and 
human studies.41,42 Therefore, LAIs might result in more 
continuous D2 blockade and receptor upregulation/
supersensitivity compared with OAPs. This effect would 
be differentially stronger when the OAPs do not consist 
of high-potency FGAs, as oral SGAs generally have less 
complete or prolonged D2 blockade.
Regarding our study methodology, 2 points require 
consideration. First, we utilized relapse rate preferen-
tially based on survival analyses as a primary outcome. 
We acknowledge that graphically calculated relapse rates 
from survival curves can result in higher relapse rates com-
pared with raw rates because the denominator decreases 
as dropout occurs. On the other hand, raw relapse rates 
do not count the potential relapse among patients who 
dropped out. Moreover, in case of systematically differ-
ent dropout rates between the treatment arms resulting in 
shorter follow-up periods in one treatment compared with 
another, a bias is introduced that disfavors the treatment 
with better acceptability and greater persistence, as more 
time is available for relapses to occur. For these reasons, 
we believe that estimated rates may yield more accurate 
data than raw relapse rates. However, we acknowledge the 
problem of using estimations, rather than observed data, 
and the mixing of estimated and raw rates from studies 
not providing survival curves. To deal with this problem, 
we analyzed the data in several ways, utilizing raw instead 
of estimated relapse rates, and using raw or estimated 
rates exclusively. The results remained the same, indepen-
dent of how relapse rates were calculated.
Second, we used each the safety/efficacy and ran-
domized population as denominators for the analyses. 
While ITT analysis is the gold standard for clinical tri-
als, ITT definitions varied, which is problematic. Some 
defined ITT as patients taking the medication at least 
once, or receiving at least one assessment (modified 
ITT), while others utilized the randomized population. 
Moreover, several studies provided survival curves and 
other results, which were solely based on the modified 
ITT sample, and 1 study26 only presented the modified 
ITT population. It is widely accepted that the reluc-
tance toward injections is an important obstacle for 
introducing LAIs.9 Some studies included in our analy-
ses reported that patients dropped out when learning 
of  their LAI allocation. We considered it important 
to include those patients as dropouts. However, given 
the fact that more studies provided data using modified 
ITT populations, we wanted to also examine the risk of 
relapse once patients are on LAIs. Therefore, we ana-
lyzed the results in both populations separately, which 
we considered the most conservative strategy, and there 
were no important differences.
Results of these analyses have to be interpreted in the 
context of several limitations. First, the database, though 
larger than in the previous meta-analysis, is still limited. 
For example, no long-term RCTs comparing paliperi-
done-LAI or aripiprazole-LAI with OAPs were available. 
Furthermore, relapse definitions varied. We utilized each 
study-defined relapse measure, and if  no definition was 
available, we used the most-appropriate relapse-related 
outcome, ie, predominantly psychiatric hospitaliza-
tion. The problem of heterogeneously defined relapse is 
not surprising because there is no universally accepted 
definition. On the other hand, this heterogeneity and 
broad-based definition could also serve to enhance the 
generalizability of the results. There was a 14-year gap 
between the last study published in 1991 and the next 
study published in 2005, which enabled us to examine 
the effect of time when the study was conducted. Because 
clinical and diagnostic concepts of the disease and thera-
peutic environments have changed over time, it is unclear, 
which factors in addition to the almost exclusive study 
of FGA-LAIs earlier and of SGA-LAIs later may have 
influenced the results. In addition, heterogeneity of the 
results was seen. Although the majority of studies tar-
geted chronic patients with over 10 years of illness, some 
targeted patients with even longer illness duration,12 while 
some targeted relatively early-onset patients.43,44 One study 
included patients with aggressive behavior,24 another 
included patients who were hospitalized throughout the 
study.23 Such clinical characteristics and different treat-
ment settings may have caused heterogeneity. Of note, 
risperidone-LAI studies were found to be most heteroge-
neous (τ2 = 0.09, I2 = 74%, Q = 30.92, df = 8, P = .0001). 
Moreover, the reporting of drop out due to “adverse 
events” is not always unambiguously restricted to physi-
ologic/physical adverse effects. Rather, at times, discon-
tinuation due to potential inefficacy-related outcomes, 
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eg, anxiety, agitation, and worsening of psychosis, may 
be counted as a side effect-related discontinuation, which 
complicates the interpretation of this outcome.
Further limitations regarding the design of the ana-
lyzed studies include issues like treatment concealment 
(7/21 were open studies), in- vs outpatient status (6/21 
included inpatients throughout the study, or presumably 
a significant portion of the study), study duration (6/21 
were <1 year), and medication allocation (10/21 used dif-
ferent medications in the LAI and OAP arms). We con-
sider the double-blind, double-dummy design favorable, 
as it reduces expectancy and rater biases. At the same time, 
however, this design itself is very different from clinical 
practice, and might have contributed to increased selec-
tion bias. Moreover, inpatient studies apparently ensured 
adherence, which may have strengthened the efficacy of the 
OAP arm. Because nonadherence can increase over time, 
one may expect also that the relative superiority of LAI 
compared with OAPs develops over time. Such an effect 
may explain the lower risk ratio in the longer term studies 
when we analyzed separately results from studies lasting 
<1 year (RR = 1.14, 95% CI: 0.82–1.58, P = .43) and those 
lasting ≥1 year (RR = 0.91, 95% CI: 0.77–1.07, P = .25). 
However, LAIs were not superior to OAPs in either 
study subgroup, and some recent studies with durations 
of ≥2 years12,14,15 also failed to show superiority of LAIs. 
This calls into question that the study duration is a major 
determinant. Using different medications in the oral and 
LAI arms makes it difficult to disentangle the independent 
efficacy of the delivery method from potential differences 
in the efficacy of the 2 drugs including inappropriate dose 
equivalency. We attempted to examine these issues by sub-
group analyses, which all yielded the same result of similar 
outcomes in the LAI and OAP groups.
In conclusion, while we had anticipated that LAIs 
(with their intrinsically better adherence) would be more 
effective than OAPs in preventing relapse, this was not 
evident in a synthesis of the available RCTs. Notably, 
these results are in contrast to naturalistic cohort stud-
ies showing superiority of LAIs in preventing rehospital-
ization. Further consideration is required to understand 
the reasons for this discrepancy. In order to evaluate the 
real-world effectivenss of LAIs compared with OAPs, 
large and long pragmatic trials are needed, which better 
resemble common clinical practice.
In our analysis, FGA-LAIs, but not SGA-LAIs, outper-
formed OAPs. The difference in effect was not statistically 
significant and in any event could be due to a cohort effect. 
The only way to determine if  the FGA/SGA distinction is 
important here would be to conduct head-to-head trials 
of FGA-LAIs vs SGA-LAIs. It is likely that some studies 
included in this analysis systematically excluded patients 
who were expected to have poor adherence. If this is true, 
then the results should not be generalized to these patients 
and do not refute the possibility that LAIs may be supe-
rior to OAPs in this important group.
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